-20℃ 3 years powder
-80℃ 2 years in solvent
BGB-102 is a potent multi-kinase inhibitor against HER2, EGFR, and HER4 (IC50s: 18 nM, 9.6 nM, and 40.3 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 mg | inquiry | inquiry | |
500 mg | inquiry | inquiry |
Description | BGB-102 is a potent multi-kinase inhibitor against HER2, EGFR, and HER4 (IC50s: 18 nM, 9.6 nM, and 40.3 nM). |
Targets&IC50 | EGFR :ic50 9.6 nM, HER2 :ic50 18 nM, HER4 :ic50 40.3 nM, |
In vivo | Compared to vehicle treatment, JNJ-26483327 (75 mg/kg, p.o.) delays xenograft tumor growth, but when combines with Herceptin, they can abrogate the PKB feedback loop and is synergistic in inhibition of xenograft tumor growth. |
Synonyms | JNJ-26483327 |
Purity | 98.00% |
Molecular Weight | 457.36 |
Formula | C22H25BrN4O2 |
CAS No. | 807640-87-5 |
-20℃ 3 years powder
-80℃ 2 years in solvent
( < 1 mg/ml refers to the product slightly soluble or insoluble )
Safe and effective drug dosing is necessary, regardless of its purpose of administration. Learn More
bottom
Answers to questions you may have can be found in the Inhibitor Handling Instructions. Topics include how to prepare stock solutions, how to store Products, and issues that need special attention for cell-based assays and animal experiments.